23/05/2025
We're still only just beginning to understand the impact that bacteria in our bodies have. In particular the gut which is a major driver for many other systems in the body. The same applies to our stock and our pets. It was never chosen as just a catchy name but we truly believe there's bigger things to come in the world of probiotics. Viva la révolution!!!
https://www.facebook.com/share/p/1ASi9Aisxr/
Recent research has unveiled significant links between gut microbiota and multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system.
Studies indicate that specific bacterial species in the gut may influence the onset and progression of MS.
Key Findings:
Akkermansia muciniphila and Acinetobacter calcoaceticus: Elevated levels of these bacteria have been observed in MS patients.
They are associated with pro-inflammatory responses, potentially exacerbating MS symptoms .
Clostridium perfringens: This bacterium produces epsilon toxin, which may compromise the blood-brain barrier, allowing harmful immune cells to attack nerve tissues .
Beneficial Bacteria: Reduced levels of bacteria like Faecalibacterium prausnitzii and Prevotella spp., known for their anti-inflammatory properties, have been noted in MS patients .
Therapeutic Implications:
Understanding the gut-brain axis—the communication network between the gut microbiota and the central nervous system—opens avenues for novel MS treatments.
Potential strategies include:
Dietary Interventions: Diets like the ketogenic diet have shown promise in modulating gut bacteria to produce anti-inflammatory compounds, potentially alleviating MS symptoms .
Probiotics and Prebiotics: Introducing beneficial bacteria or promoting their growth may restore a healthy gut microbiome balance.
F***l Microbiota Transplantation (FMT): Transferring gut microbiota from healthy donors to MS patients is being explored as a treatment option.
Conclusion:
The gut microbiome plays a crucial role in MS pathogenesis.
Targeting specific gut bacteria offers promising therapeutic avenues, emphasizing the need for further research into microbiota-based interventions for MS management.